Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial
Introduction Prone positioning (PP) is an effective first-line intervention to treat patients with moderate to severe acute respiratory distress syndrome (ARDS) receiving invasive mechanical ventilation, as it improves gas exchanges and reduces mortality. The use of PP in awake spontaneous breathing...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-11-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/10/11/e041520.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846152062833786880 |
|---|---|
| author | Jie Li Yonatan Perez Jean-Pierre Frat Stephan Ehrmann Elsa Tavernier Bairbre McNicholas Ivan Pavlov Oriol Roca John Laffey Sara Mirza David Cosgrave David Vines |
| author_facet | Jie Li Yonatan Perez Jean-Pierre Frat Stephan Ehrmann Elsa Tavernier Bairbre McNicholas Ivan Pavlov Oriol Roca John Laffey Sara Mirza David Cosgrave David Vines |
| author_sort | Jie Li |
| collection | DOAJ |
| description | Introduction Prone positioning (PP) is an effective first-line intervention to treat patients with moderate to severe acute respiratory distress syndrome (ARDS) receiving invasive mechanical ventilation, as it improves gas exchanges and reduces mortality. The use of PP in awake spontaneous breathing patients with ARDS secondary to COVID-19 was reported to improve oxygenation in few retrospective trials with small sample size. High-level evidence of awake PP for hypoxaemic patients with COVID-19 patients is still lacking.Methods and analysis The protocol of this meta-trial is a prospective collaborative individual participant data meta-analysis of randomised controlled open label superiority trials. This design is particularly adapted to a rapid scientific response in the pandemic setting. It will take place in multiple sites, among others in USA, Canada, Ireland, France and Spain. Patients will be followed up for 28 days. Patients will be randomised to receive whether awake PP and nasal high flow therapy or standard medical treatment and nasal high flow therapy. Primary outcome is defined as the occurrence rate of tracheal intubation or death up to day 28. An interim analysis plan has been set up on aggregated data from the participating research groups.Ethics and dissemination Ethics approvals were obtained in all participating countries. Results of the meta-trial will be submitted for publication in a peer-reviewed journal. Each randomised controlled trial was registered individually, as follows: NCT04325906, NCT04347941, NCT04358939, NCT04395144 and NCT04391140. |
| format | Article |
| id | doaj-art-88c8c7e91864429f9dd39eef2f4a5cb8 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2020-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-88c8c7e91864429f9dd39eef2f4a5cb82024-11-26T22:50:08ZengBMJ Publishing GroupBMJ Open2044-60552020-11-01101110.1136/bmjopen-2020-041520Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trialJie Li0Yonatan Perez1Jean-Pierre Frat2Stephan Ehrmann3Elsa Tavernier4Bairbre McNicholas5Ivan Pavlov6Oriol Roca7John Laffey8Sara Mirza9David Cosgrave10David Vines11Department of Cardiopulmonary Sciences, Division of Respiratory Care, Rush University, Chicago, Illinois, USAMédecin Intensive Réanimation, CIC 1415, CRICS-TriggerSEP, Centre d`étude des pathologies respiratoires, INSERM U1100, Université de Tours, CHU Tours, Tours, Centre, FranceMédecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, FranceMédecin Intensive Réanimation, CIC 1415, CRICS-TriggerSEP, Centre d`étude des pathologies respiratoires, INSERM U1100, Université de Tours, Centre Hospitalier Régional Universitaire de Tours, Tours, Centre, FranceBiostatistics Department, Clinical Investigation Center-1415 INSERM, CHU Tours, Tours, FranceDepartment of Anaesthesia and Intensive Care Medicine, School of Medicine, National University of Ireland Galway, Galway, IrelandDepartment of Emergency Medicine, Hopital de Verdun, Montreal, Quebec, CanadaCritical Care Department, Vall d`Hebron University Hospital, Vall d`Hebron Research Institute, Barcelona, Catalunya, SpainDepartment of Anaesthesia and Intensive Care Medicine, School of Medicine, National University of Ireland Galway, Galway, IrelandDepartment of Cardiopulmonary Sciences, Division of Respiratory Care, Rush University, Chicago, Illinois, USADepartment of Anaesthesia and Intensive Care Medicine, School of Medicine, National University of Ireland Galway, Galway, IrelandDepartment of Cardiopulmonary Sciences, Division of Respiratory Care, Rush University, Chicago, Illinois, USAIntroduction Prone positioning (PP) is an effective first-line intervention to treat patients with moderate to severe acute respiratory distress syndrome (ARDS) receiving invasive mechanical ventilation, as it improves gas exchanges and reduces mortality. The use of PP in awake spontaneous breathing patients with ARDS secondary to COVID-19 was reported to improve oxygenation in few retrospective trials with small sample size. High-level evidence of awake PP for hypoxaemic patients with COVID-19 patients is still lacking.Methods and analysis The protocol of this meta-trial is a prospective collaborative individual participant data meta-analysis of randomised controlled open label superiority trials. This design is particularly adapted to a rapid scientific response in the pandemic setting. It will take place in multiple sites, among others in USA, Canada, Ireland, France and Spain. Patients will be followed up for 28 days. Patients will be randomised to receive whether awake PP and nasal high flow therapy or standard medical treatment and nasal high flow therapy. Primary outcome is defined as the occurrence rate of tracheal intubation or death up to day 28. An interim analysis plan has been set up on aggregated data from the participating research groups.Ethics and dissemination Ethics approvals were obtained in all participating countries. Results of the meta-trial will be submitted for publication in a peer-reviewed journal. Each randomised controlled trial was registered individually, as follows: NCT04325906, NCT04347941, NCT04358939, NCT04395144 and NCT04391140.https://bmjopen.bmj.com/content/10/11/e041520.full |
| spellingShingle | Jie Li Yonatan Perez Jean-Pierre Frat Stephan Ehrmann Elsa Tavernier Bairbre McNicholas Ivan Pavlov Oriol Roca John Laffey Sara Mirza David Cosgrave David Vines Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial BMJ Open |
| title | Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial |
| title_full | Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial |
| title_fullStr | Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial |
| title_full_unstemmed | Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial |
| title_short | Awake prone positioning of hypoxaemic patients with COVID-19: protocol for a randomised controlled open-label superiority meta-trial |
| title_sort | awake prone positioning of hypoxaemic patients with covid 19 protocol for a randomised controlled open label superiority meta trial |
| url | https://bmjopen.bmj.com/content/10/11/e041520.full |
| work_keys_str_mv | AT jieli awakepronepositioningofhypoxaemicpatientswithcovid19protocolforarandomisedcontrolledopenlabelsuperioritymetatrial AT yonatanperez awakepronepositioningofhypoxaemicpatientswithcovid19protocolforarandomisedcontrolledopenlabelsuperioritymetatrial AT jeanpierrefrat awakepronepositioningofhypoxaemicpatientswithcovid19protocolforarandomisedcontrolledopenlabelsuperioritymetatrial AT stephanehrmann awakepronepositioningofhypoxaemicpatientswithcovid19protocolforarandomisedcontrolledopenlabelsuperioritymetatrial AT elsatavernier awakepronepositioningofhypoxaemicpatientswithcovid19protocolforarandomisedcontrolledopenlabelsuperioritymetatrial AT bairbremcnicholas awakepronepositioningofhypoxaemicpatientswithcovid19protocolforarandomisedcontrolledopenlabelsuperioritymetatrial AT ivanpavlov awakepronepositioningofhypoxaemicpatientswithcovid19protocolforarandomisedcontrolledopenlabelsuperioritymetatrial AT oriolroca awakepronepositioningofhypoxaemicpatientswithcovid19protocolforarandomisedcontrolledopenlabelsuperioritymetatrial AT johnlaffey awakepronepositioningofhypoxaemicpatientswithcovid19protocolforarandomisedcontrolledopenlabelsuperioritymetatrial AT saramirza awakepronepositioningofhypoxaemicpatientswithcovid19protocolforarandomisedcontrolledopenlabelsuperioritymetatrial AT davidcosgrave awakepronepositioningofhypoxaemicpatientswithcovid19protocolforarandomisedcontrolledopenlabelsuperioritymetatrial AT davidvines awakepronepositioningofhypoxaemicpatientswithcovid19protocolforarandomisedcontrolledopenlabelsuperioritymetatrial |